Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shelhigh

This article was originally published in The Gray Sheet

Executive Summary

Humanitarian device exemption for Shelhigh's pulmonic valve conduit Model NR-4000 with "No-React" treatment is approved by FDA Nov. 8. The device is indicated for "replacement of the diseased, damaged, or absent pulmonic artery in small children or infants up to age 4 years, with transposition of the great arteries, truncus arteriosis, tetrology of fallot with associated cardiac anomalies or with pulmonary atresia, or replacement of failed conduits in young patients with accelerated conduit failure." The agency is requiring the firm to track the device because it is a permanent implant, the failure of which would be likely to have serious adverse consequences
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT012619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel